Who Generates Higher Gross Profit? Teva Pharmaceutical Industries Limited or Grifols, S.A.

Teva vs. Grifols: A Decade of Gross Profit Trends

__timestampGrifols, S.A.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014169921400011056000000
Thursday, January 1, 2015193099800011356000000
Friday, January 1, 2016191229100011859000000
Sunday, January 1, 2017215201100010825000000
Monday, January 1, 201820495600008296000000
Tuesday, January 1, 201923412320007536000000
Wednesday, January 1, 202022551650007725000000
Friday, January 1, 202119625960007594000000
Saturday, January 1, 202222315300006973000000
Sunday, January 1, 202323227010007646000000
Monday, January 1, 20248064000000
Loading chart...

Data in motion

A Tale of Two Giants: Teva vs. Grifols in Gross Profit

In the competitive landscape of the pharmaceutical industry, Teva Pharmaceutical Industries Limited and Grifols, S.A. have been key players. From 2014 to 2023, Teva consistently outperformed Grifols in terms of gross profit, with Teva's figures averaging around 9 billion USD annually, nearly four times that of Grifols. However, the trend reveals a narrowing gap. Teva's gross profit peaked in 2016 and has since declined by approximately 35%, while Grifols has shown a steady increase, growing by about 37% over the same period. This shift highlights Grifols' strategic advancements and Teva's challenges in maintaining its lead. As the industry evolves, these trends underscore the dynamic nature of pharmaceutical economics and the importance of strategic positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025